April 22, 2025
In the USA in 1997-2009, influenza and RSV in total killed 30,400 people per year. Such common viral infections are well worth curing as soon as possible.
Focus on the Viral Infection, Then on the Complications
Covid brought an explosion in respiratory virus research. This is explained in part by the fact that covid is caused by a respiratory virus that's relatively potent. Most severe cases, for instance, feature destructive clotting.
Even so, covid and common colds both start with virus buildup in the respiratory system and then cause further complications, in the lungs and elsewhere. Also, covid and common colds both are more deadly to people who are elderly or have complicating conditions.
Since covid and common colds have features in common, and covid has further severe effects, covid can be taken as a generally worst case. Prevention and treatment suitable for covid should be conservatively more-than-sufficient for common colds.
From the outset, it clearly was impossible to meaningfully slow the spread of the covid-producing SARS-CoV-2 virus across whole networks of people. It was far-more practical to instead prevent covid disease development or worsening.
People prevented covid disease development by using safe, inexpensive, widely-available vitamins, supplements, and other treatments to build up immune function, lessen viral loads, and augment immune function. To build up immune function, people took vitamin D in advance in a good-enough form, in large-enough amounts, for long enough. To lessen viral loads, people didn't wear masks and further breathed plenty of fresh air, and used nasal sprays and mouthwashes. To augment immune function, people took ionophores like ivermectin, hydroxychloroquine, or quercetin, all of which transport zinc into cells, and in combination took enough zinc.
Overall, treatments were tailored to the disease phases, as outlined in Figure 1.
Figure 1. Covid time course and treatment
Treatments first primarily limited virus replication, and then primarily prevented or limited inflammation and further disease. Similar approaches work well on other similar-enough diseases.
After a Texas child tested positive for measles and then died, her also-infected four younger siblings and two 4-month-old twin cousins responded well to similar safe, widely-available treatments suitable for measles. Measles depletes vitamin A, and cod liver oil served as a high-quality source. These children's measles was in measles's respiratory phase, and budesonide steroid inhaler was very beneficial.
Admit We Have Problems Practicing and Learning
Figure 1 is from a series of prevention and treatment guides prepared by the Independent Medical Alliance. Such leading clinical practice and teaching is being suppressed by establishment groups.
Two of IMA's seven exceptional founding members, Paul Marik and Pierre Kory, had their board certifications revoked by the American Board of Internal Medicine. IMA senior fellow Mary Talley Bowden helped a hospitalized desperately-ill man's wife get a court order to get him ivermectin, and tried to get ivermectin administered to him, but this was prevented and the man died. Bowden was then sued by the 𝕏 Texas Medical Board. The distinguished lead author of the first published early outpatient treatment protocol for covid, Peter McCullough, had his board certification revoked by ABIM. Independent clinicians' prescriptions for generic antivirals have been going unfilled in hospitals and pharmacy chains.
Independent clinicians and customers have been working around pharmacists' interference with medical practice and liberty by getting prescriptions filled in some independent pharmacies and in many compounding pharmacies. State legislators have made ivermectin over-the-counter with a pharmacist's consents in Tennessee and with no exceptions in Arkansas and Idaho, and they're considering bills in Alabama, Georgia, Kentucky, Louisiana, Maine, Minnesota, Missouri, New Hampshire, North Carolina, Oklahoma, Pennsylvania, South Carolina, Texas, and 𝕏 West Virginia. They're considering banning mRNA therapies for humans in Idaho, Iowa, Kentucky, New York, South Carolina, and 𝕏 Texas.
Use Basic Controls that Are Simple and Powerful
The key disputes involve two groups. One group is pharma, plus most government people, health‑payment providers, hospitals, large practices, and pharmacy chains. The other group is independent clinicians and customers, plus a few government people and pharmacists.
Pharma's approach and independents' approach differ greatly in safety, efficacy, and cost, as encapsulated by Figure 2.
Figure 2. Pharma approach vs. independent approach
Pharma develops branded treatments by learning from small, centralized trials-first of safety, then of efficacy. This process builds in high costs and long delays.
Independents use mechanistic understanding to apply possible treatments to both existing and new uses. They start with safety data that's sufficient to support wide use, and that's often far-more extensive than the data for new pharma branded treatments. They keep monitoring safety in use, and they also monitor efficacy in use. Independents' mix of branded, generic, and other therapies is more varied. With this decentralized approach, independents discover quickly and adapt quickly, saving lives and improving health.
Aircraft carrier flight-deck crews have demonstrated high reliability by not relying on redundant operations or layers of supervision but instead keeping responsibility simple and clear, and empowering people. Clinicians face analogous real-time demands. They do well when they create for themselves a similar decentralized structure.
Vaccines and mRNA therapies appear to at minimum worsen immune responses: they reduce some crucial helpful responses, and they increase some serious harmful responses. Relying instead on less-immune-disruptive state-of-the-art preventions and treatments would very‑advisably first do no harm. In the meantime, though, autism, other historically-rare serious diseases, and turbo cancers-all of them terrible burdens on life and health-remain on the rise.
Remarkably, independents trying safe, inexpensive, widely-available treatments at small-scale on clinical cases are seeing impressive, highly-promising results on cancers. Imagine if independents could help people in case after case their whole careers, by practicing using the products they already have at hand and using more products as producers make them available.
At the end of My Cousin Vinny, Mona Lisa Vito playfully teased that succeeding in case after case would be a nightmare. We need decentralized independents to be a dream come true.